This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Compugen (CGEN) a New Strong Buy Stock
by Zacks Equity Research
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
by Zacks Equity Research
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer
Compugen (CGEN) Reports Q3 Loss
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.
Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Compugen has been struggling lately, but the selling pressure may be coming to an end soon.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Bristol-Myers Reports Disappointing Data From SCLC Study
by Zacks Equity Research
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
by Zacks Equity Research
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
Market Has Not Yet Noticed Potential in Compugen; Have You?
by Zacks Equity Research
Compugen (CGEN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Company News For Oct 10, 2017
by Zacks Equity Research
Companies in the news are: MZOR,CGEN,KTWO,AXTA
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session
by Zacks Equity Research
Compugen Ltd. (CGEN) shares rose over 10% in the last trading session.
New Strong Buy Stocks for October 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for October 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include AMRN, CGEN, RPTP, MT and HOV.